Ligand Pharmaceuticals Inc (LGND)
86.06
+1.04
(+1.22%)
USD |
NASDAQ |
May 17, 16:00
86.01
-0.05
(-0.06%)
After-Hours: 20:00
Ligand Pharmaceuticals Price to Book Value: 1.917 for May 17, 2024
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| May 17, 2024 | 1.917 |
| May 16, 2024 | 1.894 |
| May 15, 2024 | 1.910 |
| May 14, 2024 | 1.900 |
| May 13, 2024 | 1.872 |
| May 10, 2024 | 1.944 |
| May 09, 2024 | 1.918 |
| May 08, 2024 | 1.790 |
| May 07, 2024 | 1.631 |
| May 06, 2024 | 1.622 |
| May 03, 2024 | 1.646 |
| May 02, 2024 | 1.610 |
| May 01, 2024 | 1.590 |
| April 30, 2024 | 1.556 |
| April 29, 2024 | 1.569 |
| April 26, 2024 | 1.571 |
| April 25, 2024 | 1.567 |
| April 24, 2024 | 1.581 |
| April 23, 2024 | 1.556 |
| April 22, 2024 | 1.526 |
| April 19, 2024 | 1.614 |
| April 18, 2024 | 1.612 |
| April 17, 2024 | 1.753 |
| April 16, 2024 | 1.776 |
| April 15, 2024 | 1.773 |
| Date | Value |
|---|---|
| April 12, 2024 | 1.808 |
| April 11, 2024 | 1.810 |
| April 10, 2024 | 1.795 |
| April 09, 2024 | 1.811 |
| April 08, 2024 | 1.769 |
| April 05, 2024 | 1.733 |
| April 04, 2024 | 1.733 |
| April 03, 2024 | 1.661 |
| April 02, 2024 | 1.627 |
| April 01, 2024 | 1.636 |
| March 31, 2024 | |
| March 28, 2024 | 1.846 |
| March 27, 2024 | 1.800 |
| March 26, 2024 | 1.734 |
| March 25, 2024 | 1.749 |
| March 22, 2024 | 1.794 |
| March 21, 2024 | 1.843 |
| March 20, 2024 | 1.847 |
| March 19, 2024 | 1.824 |
| March 18, 2024 | 1.822 |
| March 15, 2024 | 1.796 |
| March 14, 2024 | 1.817 |
| March 13, 2024 | 1.838 |
| March 12, 2024 | 1.828 |
| March 11, 2024 | 1.825 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
1.283
Minimum
Nov 04 2022
4.891
Maximum
Feb 09 2021
2.208
Average
2.062
Median
Mar 17 2023
Price to Book Value Benchmarks
| ANI Pharmaceuticals Inc | 2.849 |
| Annovis Bio Inc | -- |
| United Therapeutics Corp | 2.280 |
| ADMA Biologics Inc | 13.89 |
| Blueprint Medicines Corp | 21.15 |
Price to Book Value Related Metrics
| PE Ratio | 16.18 |
| PS Ratio | 12.89 |
| PEG Ratio | 0.0502 |
| Price | 86.06 |
| Earnings Yield | 6.18% |
| Market Cap | 1.546B |
| PEGY Ratio | 0.0502 |
| Normalized PE Ratio | 268.14 |